Bayer/Onyx sorafenib accepted into Pilot 1
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Bayer/Onyx' oncologic sorafenib (formerly BAY 43-9006) is accepted into FDA's continuous marketing application Pilot 1 program, the firms announce May 4. The acceptance pertains to the dual RAF kinase/VEGF inhibitor's use in renal cell carcinoma. Bayer/Onyx said an NDA is "in the preparation stages"; the sponsors continue to project a first-half 2006 approval for metastatic RCC. A separate Phase III clinical program in hepatocellular carcinoma began in March (1Pharmaceutical Approvals Monthly March 2005, In Brief)...
You may also be interested in...
Bayer/Onyx 43-9006 in Phase III for HCC
Bayer/Onyx are starting a Phase III study of their oral RAF kinase/VEGF inhibitor 43-9006 (sorafenib) for use as monotherapy in advanced hepatocellular carcinoma, the firms say March 8. Five hundred patients without prior systemic treatment will be randomized in the double-blind, placebo-controlled trial; overall survival, time to symptom progression and time to tumor progression will be assessed. Median survival was 9.2 months and median time to progression was 4.2 months in a Phase II HCC trial. Bayer/Onyx originally planned to submit 43-9006 for renal cell carcinoma based on Phase II data, but are now waiting for results from an 800-patient Phase III study (1Pharmaceutical Approvals Monthly November 2004, p. 35). Both Phase III trials received special protocol assessments from FDA...
Takeda, Astellas Found New JV To Support Japanese Bioventures
Major Japanese companies Takeda, Astellas and SMBC are joining hands to establish a new joint venture with $3.9m capital and based in Japan’s largest biocluster Shonan iPark to help incubate local biopharma start-ups.
Could Eledon’s Anti-CD40L Change Transplant Medicine?
Eledon Pharmaceuticals’ CD40 Ligand blocker has yielded impressive results for post-transplant immunosuppression and cutting-edge transplant doctors have also used it for pig-to-human kidney and heart transplants, opening up the field of xenotransplantation.